Alzamend Neuro (ALZN) Corporate presentation summary

Company overview

• Focuses on developing treatments for Alzheimer's, Bipolar Disorder, Major Depressive Disorder, and PTSD using two proprietary therapeutics licensed from a leading research institution.

• Lead candidate AL001 is a patented ionic cocrystal of lithium targeting multiple neuropsychiatric indications, with potential to replace current lithium therapies.

• ALZN002 is a cell-based therapeutic vaccine aiming to restore immune response against Alzheimer's Disease.

• Headquarters in Atlanta, Georgia, and listed on NASDAQ since June 2021.

Pipeline and clinical progress

• AL001 completed Phase I and IIA trials, showing safety, bioequivalence, and superior brain delivery; Phase II trials initiated for Bipolar Disorder and planned for Alzheimer's, MDD, and PTSD in 2026.

• ALZN002 Phase I/IIA trial for Alzheimer's was initiated in 2023, paused in 2024, and expected to resume in 2026.

• Preclinical studies show AL001 improves brain bioavailability and cognitive function, with reduced toxicity compared to lithium carbonate.

• ALZN002 preclinical data demonstrate strong, long-lasting antibody responses without increased inflammation, supporting its vaccine hypothesis.

Market opportunity

• Combined U.S. patient population for target indications exceeds 48 million, with a global population over 680 million.

• AL001 and ALZN002 address significant unmet needs in neuropsychiatric and neurodegenerative disorders.